KPHMW KIORA PHARMACEUTICALS INC

Price Chart

Executive Summary

Kiora Pharmaceuticals' S-3 shelf registration (File No. 333-295994) became effective on May 22, 2026, enabling the resale of up to 11,797,088 shares of common stock by selling stockholders, including shares from an April 2026 private placement and underlying pre-funded and common stock purchase warrants. The company will not receive proceeds from share resales but may receive cash from warrant exercises. This creates a potential overhang of up to ~11.8M shares (at ~$2.58/share as of May 14, 2026) over the existing float, though actual dilution depends on warrant exercise and selling activity.

Actionable Insight

Key Facts

• S-3 shelf became effective May 22, 2026, covering resale of up to 11,797,088 shares of common stock.
• Shares include 438,471 from April 2026 private placement, 1,527,710 underlying pre-funded warrants, 7,864,726 underlying Tranche A-1 warrants, and 1,966,181 underlying Tranche A-2 warrants.
• Kiora receives no proceeds from share resales; only cash from warrant exercises if exercised.
• Common stock (KPRX) closed at $2.58 on May 14, 2026 on Nasdaq.
• The shelf was filed 8 days prior (May 18, 2026) and became effective quickly.
• Cross-filing context: S-3 filed 8 days ago — shelf now live for takedowns.

Financial Impact

Up to 11.8M shares of potential dilution overhang; at $2.58/share, total potential market value ~$30.4M. Actual dilution depends on warrant exercise and selling by holders.

Risk Factors

• Significant dilution overhang if warrants are exercised and shares sold into the market.
• Selling stockholders may sell shares at any time, creating downward price pressure.
• No proceeds to the company from share resales — dilution without capital infusion.
• OTC-traded warrants (KPHMW) may see volatility tied to common stock price movements.

Market Snapshot

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status

Related Tickers